KRM-III

• Description:

  KRM-III is a potent and orally active T-cell antigen receptor (TCR) inhibitor. KRM-III inhibits TCR- and phorbol myristate acetate/ionomycin-induced activation of nuclear factor of activated T cells (NFAT) and T-cell proliferation with an IC50 of ~5 μM. Anti-inflammatory activity[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H319

• Target:

  Nuclear Factor of activated T Cells (NFAT)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/krm-iii.html

• Concentration:

  10mM

• Purity:

  98.08

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  S=C1NC (C2=CC=CC=C2) =CN1C3=CC=CC=C3

• Molecular Formula:

  C15H12N2S

• Molecular Weight:

  252.33

• Precautions:

  H319

• References & Citations:

  [1]Eun Joo Jung, et al. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model. J Pharmacol Exp Ther. 2009 Dec;331 (3) :1005-13.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  79220-94-3